Afzal Ansari

Mr. Afzal Ansari

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2019 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
RKRekha Khandia
Rekha Khandia
SSSHAILJA SINGHAL
SHAILJA SINGHAL
Utsang KumarUtsang Kumar
Utsang Kumar
AAAfzal Ansari
Afzal Ansari
RTRuchi Tiwari
Ruchi Tiwari
RSRaj Kumar Singh
Raj Kumar Singh
A recent outbreak of Nipah virus (NiV) in India has caused 17 deaths in people living in districts of Kerala state. Its zoonotic nature, as well as high rate of human-to-human transmission, has led researchers worldwide to work toward understanding the different aspects of the NiV. We performed a codon usage analysis, based on publicly available nucleotide sequences of NiV and its host adaptation, along with other members of the Henipavirus genus in ten hosts. NiV genome encodes nine open reading frames; and overall, no significant bias in codon usage was observed. Aromaticity of proteins had no impact on codon usage. An analysis of preferred codons used by NiV and the tRNA pool in human cells indicated that NiV prefers codons from a suboptimal anticodon tRNA pool. We observed that codon usage by NiV is mainly constrained by compositional and selection pressures, not by mutational forces. Parameters that define NiV and host relatedness in terms of codon usage were analyzed, with a codon adaptation index (CAI), relative codon deoptimization index (RCDI), and similarity index calculations; which indicated that, of all hosts analyzed, NiV was best adapted to African green monkeys. A comparative analysis based on the relative codon deoptimization index (RCDI) for host adaptation of NiV, Hendra virus (HeV), Cedar virus (CedV), and Hendra like Mojiang virus (MojV) revealed that except for dogs and ferrets, all evaluated hosts were more susceptible to HeV than NiV.

Verified
Journal Article
Open access
PDF file
DKDinesh Kumar
Dinesh Kumar
SKSwapnil Kumar
Swapnil Kumar
GAGarima Ayachit
Garima Ayachit
SBShivarudrappa B. Bhairappanavar
Shivarudrappa B. Bhairappanavar
AAAfzal Ansari
Afzal Ansari
JDJayashankar Das
Jayashankar Das
MicroRNAs (miRNAs) are well-known key regulators of gene expression primarily at the post-transcriptional level. Plant-derived miRNAs may pass through the gastrointestinal tract, entering into the body fluid and regulate the expression of endogenous mRNAs. Camptotheca acuminata, a highly important medicinal plant known for its anti-cancer potential was selected to investigate cross-kingdom regulatory mechanism and involvement of miRNAs derived from this plant in cancer-associated pathways through in silico systems biology approach. In this study, total 33 highly stable putative novel miRNAs were predicted from the publically available 53,294 ESTs of C. acuminata, out of which 14 miRNAs were found to be regulating 152 target genes in human. Functional enrichment, gene-disease associations and network analysis of these target genes were carried out and the results revealed their association with prominent types of cancers like breast cancer, leukemia and lung cancer. Pathways like focal adhesion, regulation of lipolysis in adipocytes and mTOR signaling pathways were found significantly associated with the target genes. The regulatory network analysis showed the association of some important hub proteins like GSK3B, NUMB, PEG3, ITGA2 and DLG2 with cancer-associated pathways. Based on the analysis results, it can be suggested that the ingestion of the C. acuminata miRNAs may have a functional impact on tumorigenesis in a cross-kingdom way and may affect the physiological condition at genetic level. Thus, the predicted miRNAs seem to hold potentially significant role in cancer pathway regulation and therefore, may be further validated using in vivo experiments for a better insight into their mechanism of epigenetic action of miRNA.

3 June 2015 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
ADAditi Daga
Aditi Daga
AAAfzal Ansari
Afzal Ansari
SPShanaya Patel
Shanaya Patel
SMSheefa Mirza
Sheefa Mirza
RRRakesh M. Rawal
Rakesh M. Rawal
VUValentina Umrania
Valentina Umrania
Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities Lung cancer;driver mutation;translocation;drug target;targeted therapy;acquired resistance;NSCLC; Lung cancer is a serious health problem and leading cause of death worldwide due to its high incidence and mortality. More than 80% of lung cancers feature a non-small cell histology. Over few decades, systemic chemotherapy and surgery are the only treatment options in this type of tumor but due to their limited efficacy and overall poor survival of patients, there is an urge to develop newer therapeutic strategies which circumvent the problems. Enhanced knowledge of translational science and molecular biology have revealed that lung tumors carry diverse driver gene mutations and adopt different intracellular pathways leading to carcinogenesis. Hence, the development of targeted agents against molecular subgroups harboring critical mutations is an attractive approach for therapeutic treatment. Targeted therapies are clearly more preferred nowadays over systemic therapies because they target tumor specific molecules resulting with enhanced activity and reduced toxicity to normal tissues. Thus, this review encompasses comprehensive updates on targeted therapies for the driver mutations in non-small cell lung cancer (NSCLC) and the potential challenges of acquired drug resistance faced i n the field of targeted therapy along with the imminent newer treatment modalities against lung cancer.

19 March 2021 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
MJMadhvi Joshi
Madhvi Joshi
APApurvasinh Puvar
Apurvasinh Puvar
DKDinesh Kumar
Dinesh Kumar
AAAfzal Ansari
Afzal Ansari
MPMaharshi Pandya
Maharshi Pandya
CJChaitanya Joshi
Chaitanya Joshi
Humanity has seen numerous pandemics during its course of evolution. The list includes several incidents from the past, such as measles, Ebola, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS), etc. The latest edition to this is coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of August 18, 2020, COVID-19 has affected over 21 million people from 180 + countries with 0.7 million deaths across the globe. Genomic technologies have enabled us to understand the genomic constitution of pathogens, their virulence, evolution, and rate of mutation, etc. To date, more than 83,000 viral genomes have been deposited in public repositories, such as GISAID and NCBI. While we are writing this, India is the third most affected country by COVID-19, with 2.7 million cases and > 53,000 deaths. Gujarat is the 11th highest affected state with a 3.48% death rate compared to the national average of 1.91%. In this study, a total of 502 SARS-CoV-2 genomes from Gujarat were sequenced and analyzed to understand its phylogenetic distribution and variants against global and national sequences. Further variants were analyzed from diseased and recovered patients from Gujarat and the world to understand its role in pathogenesis. Among the missense mutations present in the Gujarat SARS-CoV-2 genomes, C28854T (Ser194Leu) had an allele frequency of 47.62 and 7.25% in deceased patients from the Gujarat and global datasets, respectively. In contrast, the allele frequency of 35.16 and 3.20% was observed in recovered patients from the Gujarat and global datasets, respectively. It is a deleterious mutation present in the nucleocapsid (N) gene and is significantly associated with mortality in Gujarat patients with a p-value of 0.067 and in the global dataset with a p-value of 0.000924. The other deleterious variant identified in deceased patients from Gujarat (p-value of 0.355) and the world (p-value of 2.43E-06) is G25563T, which is located in Orf3a and plays a potential role in viral pathogenesis. SARS-CoV-2 genomes from Gujarat are forming distinct clusters under the GH clade of GISAID. This study will shed light on the viral haplotype in SARS-CoV-2 samples from Gujarat, India.

22 October 2019 in Oncotarget
Verified
Journal Article
Open access
PDF file
ISInayatullah Shaikh
Inayatullah Shaikh
AAAfzal Ansari
Afzal Ansari
GAGarima Ayachit
Garima Ayachit
MGMonika Gandhi
Monika Gandhi
PSPriyanka Sharma
Priyanka Sharma
JDJayashankar Das
Jayashankar Das
Oncotarget | https://doi.org/10.18632/oncotarget.27249 Inayatullah Shaikh, Afzal Ansari, Garima Ayachit, Monika Gandhi, Priyanka Sharma, Shivarudrappa Bhairappanavar, Chaitanya G. Joshi, Jayashankar Das

6 June 2022 in Genomics
Verified
Journal Article
Open access
RPRamesh Pandit
Ramesh Pandit
ISIndra Singh
Indra Singh
AAAfzal Ansari
Afzal Ansari
JRJanvi Raval
Janvi Raval
ZPZarna Patel
Zarna Patel
CJChaitanya Joshi
Chaitanya Joshi
Different human races across the globe responded in a different way to the SARS-CoV-2 infection leading to different disease severity. Therefore, it is anticipated that host genetic factors have a straight association with the COVID-19. We identified a total 6, 7, and 6 genomic loci for deceased-recovered, asymptomatic-recovered, and deceased-asymptomatic group comparison, respectively. Unfavourable alleles of the markers nearby the genes which are associated with lung and heart diseases such as Tumor necrosis factor superfamily (TNFSF4&18), showed noteworthy association with the disease severity and outcome for the COVID-19 patients in the western Indian population. The markers found with significant association with disease prognosis or recovery are of value in determining the individual's response to SARS-CoV-2 infection and can be used for the risk prediction in COVID-19. Besides, GWAS study in other populations from India may help to strengthen the outcome of this study.